Keywords
MedicineCancerOncologyClinical trialBreast cancerDiseaseInternal medicineTargeted therapyBioinformatics
Affiliated Institutions
Related Publications
Triple-negative breast cancer molecular subtyping and treatment progress
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth fac...
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Anti-HER2 immunoliposomes produced enhanced antitumor efficacy via targeted delivery.
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Aims: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in the development of various solid tumour types. Validated methods and scoring ...
Molecular Target Class Is Predictive of <i>In vitro</i> Response Profile
Abstract Preclinical cellular response profiling of tumor models has become a cornerstone in the development of novel cancer therapeutics. As efforts to predict clinical efficac...
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
PURPOSE Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody ...
Publication Info
- Year
- 2008
- Type
- review
- Volume
- 19
- Issue
- 9
- Pages
- 1523-1529
- Citations
- 1145
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1145
OpenAlex
Cite This
Cristina Grávalos,
Antonio Jimeno
(2008).
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.
Annals of Oncology
, 19
(9)
, 1523-1529.
https://doi.org/10.1093/annonc/mdn169
Identifiers
- DOI
- 10.1093/annonc/mdn169